BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15756428)

  • 1. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
    Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
    Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.
    Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
    Boulikas T; Stathopoulos GP; Volakakis N; Vougiouka M
    Anticancer Res; 2005; 25(4):3031-9. PubMed ID: 16080562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.
    Veal GJ; Griffin MJ; Price E; Parry A; Dick GS; Little MA; Yule SM; Morland B; Estlin EJ; Hale JP; Pearson AD; Welbank H; Boddy AV
    Br J Cancer; 2001 Apr; 84(8):1029-35. PubMed ID: 11308249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
    Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
    Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal cisplatin: a new cisplatin formulation.
    Stathopoulos GP
    Anticancer Drugs; 2010 Sep; 21(8):732-6. PubMed ID: 20671511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.
    Boulikas T
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1197-218. PubMed ID: 19604121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
    Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
    Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
    de Jonge MJ; Slingerland M; Loos WJ; Wiemer EA; Burger H; Mathijssen RH; Kroep JR; den Hollander MA; van der Biessen D; Lam MH; Verweij J; Gelderblom H
    Eur J Cancer; 2010 Nov; 46(16):3016-21. PubMed ID: 20801016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low renal toxicity of lipoplatin compared to cisplatin in animals.
    Devarajan P; Tarabishi R; Mishra J; Ma Q; Kourvetaris A; Vougiouka M; Boulikas T
    Anticancer Res; 2004; 24(4):2193-200. PubMed ID: 15330160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
    Ajani JA; Faust J; Ikeda K; Yao JC; Anbe H; Carr KL; Houghton M; Urrea P
    J Clin Oncol; 2005 Oct; 23(28):6957-65. PubMed ID: 16145066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity].
    Kitajima K; Fukuoka M; Kobayashi S; Kusunoki Y; Takada M; Negoro S; Matsui K; Sakai N; Ryu S; Takifuji N
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2517-23. PubMed ID: 3039920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study.
    Stathopoulos GP; Boulikas T; Kourvetaris A; Stathopoulos J
    Anticancer Res; 2006; 26(2B):1489-93. PubMed ID: 16619562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN).
    Jehn CF; Boulikas T; Kourvetaris A; Kofla G; Possinger K; Lüftner D
    Anticancer Res; 2008; 28(6B):3961-4. PubMed ID: 19192656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
    Ricart AD; Berlin JD; Papadopoulos KP; Syed S; Drolet DW; Quaratino-Baker C; Horan J; Chick J; Vermeulen W; Tolcher AW; Rowinsky EK; Rothenberg ML
    Clin Cancer Res; 2008 Dec; 14(23):7947-55. PubMed ID: 19047127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
    Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
    Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.